Building on earlier work where we discovered a potent combination treatment that activated both innate and T cell responses against tumors (Moynihan et al., 2016), here we show that a variety of tumor models exhibiting weak responses to ICB can be cured by it following a “priming” dose of AIP therapy comprised of an anti-tumor antibody surrogate, long half-life IL-2, and anti-PD-1. The gene discussed is IL2; the disease is neoplasm.